Lung squamous cell carcinoma metastatic

1 trials MedDRA PT
1 Registered trials
0 Recruiting
1 Unique sponsors
2 Unique IMPs
0 Commercial trials
Drug classes (ATC)
L Oncology (ATC L) 1
Mechanism of action (INN-stem analysis)
Checkpoint inhibitor (PD-L1) 1 substance
Checkpoint inhibitor (CTLA-4) 1 substance
Phase I/II: 1

Filter these 1 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 1 trials

Phase I/II

1 trial
  • Institut Gustave Roussy Academic
    DURVALUMAB; TREMELIMUMAB
    2024-514920-18-00 1 country 2017 n=61
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Institut Gustave Roussy Academic 1 Phase I/II 0
← All indication landscapes